A US-based and focused cannabis operator has completed a deal to buy a licensed producer (LP) in Canada, marking its official entry into the Canadian space.
MPX Bioceutical (CSE:MPX, OTC:MPXEF) announced on Monday (June 11) it had reached an agreement for the acquisition of all issued and outstanding shares of Canveda, a company that obtained its cultivation license last year.
Canveda’s LP asset is a 12,000 square foot facility in Peterborough, Ontario currently projected to produce 1,000-1,200 kilograms of cannabis flower per year.
Looking for Cannabis Stocks?
Read our report to find market data, important news and stocks to watch!
Details of the transaction
According to its statement, MPX will pay roughly C$18.1 million in a combination of C$3.1 million in cash, C$15 million worth of common shares issued at C$0.70 and 6 million common share purchase warrants.
“With the acquisition of Canveda, MPX has established a foothold in Canada to develop a vertically integrated business from seed to sale,” Michael Arnkvarn, executive vice president and chief marketing officer said in the statement.
During a conference call to update analysts and investors on the acquisition and general developments of the company, MPX also revealed it had reached US$5 million in revenue in March for its presence in Arizona and Nevada.
In the past, MPX has been clear with its intentions in the Canadian market by owning an Ontario facility in the application stage to become an LP. That process then stagnated which caused the company to direct its attention into the US market.
Now with the Canveda acquisition, MPX CEO Scott Boyes said it should help accelerate the process to obtain cultivation, sale and dealer licenses for the Owen Sound, Ontario facility.
On the same call, Boyes was asked how much money does the company plan to spend in Canada now with this acquisition and if Canveda affects the development plans for the facility in Owen Sound.
Looking for Cannabis Stocks?
Read our report to find market data, important news and stocks to watch!
Boyes said the company still plans to spend between C$3 and C$4 million for the development of the non-LP asset in Ontario and has shifted its cultivation capacity strategy since the company believes current LPs already have sufficient capacity for the Canadian market. Boyes said:
We think there’s going to be some downward pressure on flower and trim pricing and the only place to hold a reasonable margin is in the producing of distillates and secondary products so we no longer plan massive cultivation development in Owen Sound, we will focus on some high-end cultivation, cultivation that we can use for our own concentrate production and will focus on producing concentrates and other products.
Market reaction to LP acquisition by MPX
MPX’s share price has been trending upward since the purchase of Canveda. On Monday the company closed the trading session with a share price of C$0.92 thanks to a 4.55 percent increase.
After the Tuesday (June 12) session ended, MPX’s shares had elevated 2.17 percent and reached a price of C$0.94.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Looking for Cannabis Stocks?
Read our report to find market data, important news and stocks to watch!
The post MPX Bioceutical Buys Canadian LP Canveda appeared first on Investing News Network.
Source
Source: https://hempland.net/mpx-bioceutical-buys-canadian-lp-canveda/
